ResMed | RMD - Cash And Equivalent


ResMed reported $1.66B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Ansell USD 238.3M 674M Jun/2025
Artivion USD 55.76M 9.14M Mar/2026
AtriCure USD 146.16M 21.26M Mar/2026
Baxter International USD 2.02B 51M Mar/2026
Cochlear AUD 275.7M 107.4M Jun/2025
Cooper Companies USD 124.9M 14.3M Dec/2025
CSL USD 2.16B 633M Jun/2025
Dexcom USD 1.12B 200.5M Mar/2026
Edwards Lifesciences USD 2.4B 538M Mar/2026
Fisher Paykel Healthcare NZD 89.9M 13.3M Jun/2022
Globus Medical USD 560.95M 34.79M Mar/2026
Haemonetics USD 245.44M 117.93M Mar/2026
Idexx Laboratories USD 200.53M 20.46M Mar/2026
Inogen USD 106.48M 2.79M Sep/2025
Insulet USD 480.4M 235.7M Mar/2026
Integra LifeSciences USD 236.81M 1.76M Mar/2026
Intuitive Surgical USD 7.98B 1.05B Mar/2026
Medtronic USD 1.15B 135M Dec/2025
Philips EUR 2.79B 882M Dec/2025
Ramsay Health Care AUD 784.4M 443.3M Jun/2025
ResMed USD 1.66B 243.44M Mar/2026
Sigma Healthcare AUD 16.65M 3.68M Jan/2023
Sonic Healthcare AUD 645M 25.39M Jun/2024
Steris USD 423.7M 104.5M Dec/2025
Teleflex USD 309.41M 69.15M Mar/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026